Perrigo Extended-Release Acetaminophen Launch Delayed By QC Issues
This article was originally published in The Tan Sheet
Executive Summary
Perrigo has postponed its plans to market private label extended-release acetaminophen until it can resolve quality control issues outlined in a recent FDA warning letter.
You may also be interested in...
GMP Violations Usually Due To Poor Management Controls – FDA’s Ellsworth
The majority of recent FDA consent decrees have been due to poor oversight by senior company management, not problems inherent in firms' manufacturing controls, according to New Jersey District Director Douglas Ellsworth
Perrigo Liquid Pain Reliever Recall Prompted By Excess Acetaminophen
Perrigo is recalling nearly 8,000 bottles of cherry-flavored pain reliever suspension liquid manufactured at its Allegan, Mich. facility.
Perrigo Multiple Acquisitions Expected In Next 12 Months - CEO Gibbons
Perrigo is eyeing possible near-term acquisition candidates in three main areas - global operations, nutritionals and new delivery vehicles - as the private labeler comes closer to putting its recent operational woes behind it.